Literature DB >> 16041205

Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors.

Stefaan Mulier1, Yicheng Ni, Jacques Jamart, Theo Ruers, Guy Marchal, Luc Michel.   

Abstract

OBJECTIVE: The purpose of this study was to analyze the factors that influence local recurrence after radiofrequency coagulation of liver tumors. SUMMARY BACKGROUND DATA: Local recurrence rate varies widely between 2% and 60%. Apart from tumor size as an important risk factor for local recurrence, little is known about the impact of other factors.
METHODS: An exhaustive literature search was carried out for the period from January 1, 1990 to January 1, 2004. Only series with a minimal follow-up of 6 months and/or mean follow-up of 12 months were included. Univariate and multivariate meta-analyses were carried out.
RESULTS: Ninety-five independent series were included, allowing the analysis of the local recurrence rate of 5224 treated liver tumors. In a univariate analysis, tumor-dependent factors with significantly less local recurrences were: smaller size, neuroendocrine metastases, nonsubcapsular location, and location away from large vessels. Physician-dependent favorable factors were: surgical (open or laparoscopic) approach, vascular occlusion, general anesthesia, a 1-cm intentional margin, and a greater physician experience. In a multivariate analysis, significantly less local recurrences were observed for small size (P < 0.001) and a surgical (versus percutaneous) approach (P < 0.001).
CONCLUSIONS: Radiofrequency coagulation by laparoscopy or laparotomy results in superior local control, independent of tumor size. The percutaneous route should mainly be reserved for patients who cannot tolerate a laparoscopy or laparotomy. The short-term benefits of less invasiveness for the percutaneous route do not outweigh the longer-term higher risk of local recurrence.

Entities:  

Mesh:

Year:  2005        PMID: 16041205      PMCID: PMC1357720          DOI: 10.1097/01.sla.0000171032.99149.fe

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  139 in total

1.  Delivery of radiofrequency ablation probes to the targeted liver malignancy: using all the players on the field.

Authors:  Steven C Rose; Tarek I Hassanein; Michael Bouvet; Marquis E Hart; Ajai Khanna; M Wayne Saville
Journal:  J Vasc Interv Radiol       Date:  2002-10       Impact factor: 3.464

Review 2.  Local ablation therapy for hepatocellular carcinoma: current status and future perspectives.

Authors:  Masatoshi Kudo
Journal:  J Gastroenterol       Date:  2004       Impact factor: 7.527

3.  Hepatic ablation using radiofrequency electrocautery.

Authors:  J P McGahan; P D Browning; J M Brock; H Tesluk
Journal:  Invest Radiol       Date:  1990-03       Impact factor: 6.016

Review 4.  Complications of radiofrequency coagulation of liver tumours.

Authors:  S Mulier; P Mulier; Y Ni; Y Miao; B Dupas; G Marchal; I De Wever; L Michel
Journal:  Br J Surg       Date:  2002-10       Impact factor: 6.939

5.  Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis.

Authors:  S A Curley; F Izzo; L M Ellis; J Nicolas Vauthey; P Vallone
Journal:  Ann Surg       Date:  2000-09       Impact factor: 12.969

6.  Hepatic resection for colorectal metastases: analysis of prognostic factors.

Authors:  S Ambiru; M Miyazaki; T Isono; H Ito; K Nakagawa; H Shimizu; K Kusashio; S Furuya; N Nakajima
Journal:  Dis Colon Rectum       Date:  1999-05       Impact factor: 4.585

7.  Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications.

Authors:  T F Wood; D M Rose; M Chung; D P Allegra; L J Foshag; A J Bilchik
Journal:  Ann Surg Oncol       Date:  2000-09       Impact factor: 5.344

8.  Percutaneous radiofrequency ablation therapy after intrathoracic saline solution infusion for liver tumor in the hepatic dome.

Authors:  Toshiya Shibata; Yuji Iimuro; Iwao Ikai; Etsuro Hatano; Yoshio Yamaoka; Junji Konishi
Journal:  J Vasc Interv Radiol       Date:  2002-03       Impact factor: 3.464

9.  Value of three-dimensional US for optimizing guidance for ablating focal liver tumors.

Authors:  S C Rose; T I Hassanein; D W Easter; R A Gamagami; M Bouvet; D H Pretorius; T R Nelson; T B Kinney; G M James
Journal:  J Vasc Interv Radiol       Date:  2001-04       Impact factor: 3.464

10.  Feasibility of adjuvant hepatic arterial infusion of chemotherapy after radiofrequency ablation with or without resection in patients with hepatic metastases from colorectal cancer.

Authors:  Courtney L Scaife; Steven A Curley; Francesco Izzo; Paolo Marra; Paolo Delrio; Bruno Daniele; Franco Cremona; Jeffrey E Gershenwald; Judy L Chase; Richard D Lozano; Yehuda Z Patt; Bruno D Fornage; Jean Nicolas Vauthey; Misty L Woodall; Karen B Gonzalez; Lee M Ellis
Journal:  Ann Surg Oncol       Date:  2003-05       Impact factor: 5.344

View more
  195 in total

1.  Percutaneous stereotactic radiofrequency ablation of colorectal liver metastases.

Authors:  Reto Bale; Gerlig Widmann; Peter Schullian; Marion Haidu; Georg Pall; Alexander Klaus; Helmut Weiss; Matthias Biebl; Raimund Margreiter
Journal:  Eur Radiol       Date:  2011-11-10       Impact factor: 5.315

2.  CT-guided radiofrequency ablation as a salvage treatment of colorectal cancer hepatic metastases developing after hepatectomy.

Authors:  Constantinos T Sofocleous; Elena N Petre; Mithat Gonen; Karen T Brown; Stephen B Solomon; Anne M Covey; William Alago; Lynn A Brody; Raymond H Thornton; Michael D'Angelica; Yuman Fong; Nancy E Kemeny
Journal:  J Vasc Interv Radiol       Date:  2011-04-22       Impact factor: 3.464

3.  Effect of CT fluoroscopy-guided transpulmonary radiofrequency ablation of liver tumours on the lung.

Authors:  T Iguchi; D Inoue; K Yabushita; K Sakaguchi; M Tatsukawa; H Sasaki; S Kanazawa
Journal:  Br J Radiol       Date:  2012-02-28       Impact factor: 3.039

4.  Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004).

Authors:  T Ruers; C Punt; F Van Coevorden; J P E N Pierie; I Borel-Rinkes; J A Ledermann; G Poston; W Bechstein; M A Lentz; M Mauer; E Van Cutsem; M P Lutz; B Nordlinger
Journal:  Ann Oncol       Date:  2012-03-19       Impact factor: 32.976

Review 5.  Radiofrequency ablation versus resection for liver tumours: an evidence-based approach to retrospective comparative studies.

Authors:  Gianpiero Gravante; John Overton; Roberto Sorge; Neil Bhardwaj; Matthew S Metcalfe; David M Lloyd; Ashley R Dennison
Journal:  J Gastrointest Surg       Date:  2011-02       Impact factor: 3.452

6.  Surgical treatment of hepatocellular cancer: expert consensus conference.

Authors:  Thomas A Aloia; Alan Hemming; Myron Schwartz
Journal:  HPB (Oxford)       Date:  2010-06       Impact factor: 3.647

7.  Long-term results of radiofrequency ablation for unresectable colorectal liver metastases: a potentially curative intervention.

Authors:  A A J M Van Tilborg; M R Meijerink; C Sietses; J H T M Van Waesberghe; M O Mackintosh; S Meijer; C Van Kuijk; P Van Den Tol
Journal:  Br J Radiol       Date:  2010-12-15       Impact factor: 3.039

8.  Thermal ablation for unresectable liver tumours, time to move forward?

Authors:  Gianpiero Gravante
Journal:  World J Gastrointest Surg       Date:  2010-01-27

9.  Minimally Invasive Liver Surgery for Hepatic Colorectal Metastases.

Authors:  Ibrahim Nassour; Patricio M Polanco
Journal:  Curr Colorectal Cancer Rep       Date:  2016-03-08

Review 10.  The laparoscopic approach for radiofrequency ablation of hepatocellular carcinoma--indication, technique and results.

Authors:  Till Herbold; Roger Wahba; Christopher Bangard; Münevver Demir; Uta Drebber; Dirk L Stippel
Journal:  Langenbecks Arch Surg       Date:  2012-10-24       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.